| Overall survival | ||
---|---|---|---|
HR | 95% confidence interval | p value | |
Univariate analysis | |||
 Demographic | |||
  Sex (male vs female) | 0.887 | 0.396–1.987 | 0.770 |
  Age (< 60 vs 60+) | 1.461 | 0.625–3.414 | 0.381 |
 Cytogenetic/clinical factors | |||
  Risk groups (favorable vs intermediate vs adverse) | 2.325 | 1.183–4.569 | 0.014 |
  FLT3 (WT vs mutated) | 1.282 | 0.474–3.466 | 0.624 |
  Response (NR vs CR) | 0.213 | 0.089–0.509 | 0.001 |
  WBC count (low vs high) | 1.168 | 0.514–2.650 | 0.711 |
  LDH level (low vs high) | 0.242 | 0.101–0.584 | 0.002 |
 Methylation | |||
  CG6 (low vs high) | 0.894 | 0.386–2.068 | 0.793 |
  CG7 (low vs high) | 0.380 | 0.157–0.917 | 0.031 |
  CG8 (low vs high) | 0.762 | 0.335–1.731 | 0.516 |
  CG9 (low vs high) | 0.331 | 0.136–0.805 | 0.015 |
 Expression | |||
  DLK1 (low vs high) | 3.212 | 1.096–9.413 | 0.033 |
  MEG3 (low vs high) | 2.294 | 0.819–6.421 | 0.114 |
  DLK1/MEG3 (low vs high) | 0.668 | 0.247–1.808 | 0.428 |
Multivariate analysis | |||
 Methylation | |||
  CG7 (low vs high) | 0.533 | 0.185–1.538 | 0.245 |
  CG9 (low vs high) | 0.294 | 0.092–0.935 | 0.038 |
 Expression | |||
  DLK1 (low vs high) | 1.758 | 0.467–6.615 | 0.404 |